Abstract: The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
Type:
Grant
Filed:
March 17, 2011
Date of Patent:
June 28, 2016
Assignee:
Imperial Innovations Limited
Inventors:
Kristian Riesbeck, Anthony Dorling, Andrew John Timothy George, Robert Ian Lechler
Abstract: The invention is directed to a isolated a Piscine reovirus associated with HSMI in teleosts, and isolated nucleic acids sequences and peptides thereof. The invention also relates to diagnostic antibodies against antigens derived from Piscine reoviruses. In another aspect, the invention relates to iRNAs which target nucleic acid sequences of Piscine reoviruses. In another aspect, the invention is related to methods for detecting the presence or absence of Piscine reoviruses in an animal.
Type:
Grant
Filed:
October 4, 2010
Date of Patent:
June 14, 2016
Assignees:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE NATIONAL VETERINARY INSTITUTE
Inventors:
W. Ian Lipkin, Gustavo Palacios, Ruth Toril Kongtorp, Edgar Brun
Abstract: Disclosed are: a polypeptide marker for diagnosing arteriosclerosis; a gene marker for diagnosing arteriosclerosis; an antibody; a probe for detecting an arteriosclerosis marker gene; a DNA microarray or a DNA chip for detecting an arteriosclerosis marker gene; a method for detecting arteriosclerosis; and a kit for diagnosing arteriosclerosis; with which an arteriosclerotic lesion can be detected with much improved accuracy.
Type:
Grant
Filed:
March 4, 2013
Date of Patent:
June 14, 2016
Assignees:
Fujikura Kasei Co., Ltd., National University Corporation Chiba University
Abstract: The present invention relates to yeast strains and, in particular, to yeast stains for use in fermentation processes. The invention also relates to methods of fermentation using the yeast strains of the invention either alone or in combination with other yeast strains. The invention thither relates to methods for the selection of yeast strains suitable for fermentation cultures by screening for various metabolic products and the use of specific nutrient sources.
Type:
Grant
Filed:
March 26, 2013
Date of Patent:
June 7, 2016
Assignee:
AUCKLAND UNISERVICES LIMITED
Inventors:
Matthew Robert Goddard, Richard Clague Gardner, Nicole Anfang
Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
Type:
Grant
Filed:
February 26, 2014
Date of Patent:
June 7, 2016
Assignee:
PHICO THERAPEUTICS LTD.
Inventors:
Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
Abstract: Provided are a eukaryotic expression system and its applications. The eukaryotic expression system has a recombinant plant cell. The recombinant plant cell includes a first vector and a second vector. The first vector expresses a fusion protein containing an Asia tospoviral common epitope. The fusion protein containing Asia tospoviral common epitope consists of an amino acid sequence as set forth in SEQ ID NO. 1, and a predetermined protein fragment connecting to the Asia tospoviral common epitope. The above eukaryotic expression system is useful for monitoring the interaction between proteins via use of a specific peptide to tag the predetermined protein and demonstrates high sensitivity and stability.
Abstract: Culturing heterologous protein-secreting mammalian cells, such as CHO or BHK cells, at 35.1-36.5° C. and/or at pH 7.15-7.20 and/or at a dissolved CO2 concentration of 10% or lower. Preferred heterologous proteins are Factor VIII, ADAMTS-13, furin or Factor VII.
Abstract: Provided is an antibody production method whereby it is possible to repeatedly acquire antibodies produced by fish without killing the fish. Specifically provided is an antibody production method whereby it is possible to repeatedly acquire the antibodies produced by a fish, without killing the fish, by administering antigens to fish that have blisters.
Type:
Grant
Filed:
March 15, 2012
Date of Patent:
June 7, 2016
Assignee:
NATIONAL UNIVERSITY CORPORATION MIE UNIVERSITY
Abstract: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
Type:
Grant
Filed:
February 17, 2010
Date of Patent:
May 31, 2016
Assignee:
BAYER HEALTHCARE LLC
Inventors:
Jesper Mortensen Haaning, Kim Vilbour Andersen
Abstract: A method for fermenting a microorganism, producing a compound of interest, in a culture medium comprising: adding a browned glucose solution to the culture medium, wherein the browned glucose solution is a glucose solution that has been acid treated and heated to a temperature of at least 90 degrees Celsius, and wherein the glucose solution has a concentration of at least 500 g/l.
Abstract: Biologically active molecules are inactivated for selective activation by target cells by being covalently bonded to one or more peptides each of which has one or more specific amino acid sequences that are selected in respect of enzymes cell-specific for target cells. The bonds, which are broken exclusively by the enzymes cell-specific for the target cells in order to biologically activate the molecules, allow the molecules to remain biologically inactive in cells other than the target cells. The molecules are used for influencing gene expression of preferably sick and infected organs or cells, for example.
Abstract: Reduced genome bacteria with improved genetic stability are provided. Also provided are methods of producing polypeptides using the reduced genome bacteria with improved genetic stability.
Type:
Grant
Filed:
October 19, 2012
Date of Patent:
May 17, 2016
Assignee:
SCARAB GENOMICS, LLC
Inventors:
Frederick R. Blattner, Balint Csorgo, Gyorgy Posfai
Abstract: This invention provides methods and kits for enriching and/or detecting a nucleic acid with at least one variant nucleotide from a nucleic acid population in a sample. Methods employ the use of enriching primers and bridge-probes for enriching and detecting target nucleic acids. Extension of the enriching primer permits amplification of the target nucleic acid having the variant nucleotide.
Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
Type:
Grant
Filed:
May 29, 2014
Date of Patent:
May 10, 2016
Assignee:
Epizyme, Inc.
Inventors:
Kevin Wayne Kuntz, Sarah Kathleen Knutson, Timothy James Nelson Wigle
Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
Abstract: The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.
Type:
Grant
Filed:
September 13, 2007
Date of Patent:
May 10, 2016
Assignees:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Hua Gu, Richard Hodes, Jeffrey J. Chiang, Ihnkyung Jang
Abstract: The present invention relates to novel engineered lower eukaryotic host cells for expressing heterologous proteins and to methods of generating such strains.
Type:
Grant
Filed:
October 23, 2012
Date of Patent:
May 3, 2016
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Bo Jiang, Rebecca D. Argyros, Stephanie Nelson, Robert C. Davidson, Ronghua Chen, Jun Zhuang
Abstract: Disclosed herein is a set of E. coli single-protein production (SPP) technologies with protein NMR (SPP-NMR) for (i) using isotope-enriched membrane proteins produced with the SPP system in screening detergent conditions suitable for purification and/or three-dimensional structure analysis without the requirement for protein purification, (ii) producing 2H, 13C, 15N enriched proteins suitable for high throughput and membrane protein NMR studies, and (iii) labeling with 13C-15N specific peptide bonds in proteins (referred to herein as SPP-PBL).
Type:
Grant
Filed:
September 15, 2014
Date of Patent:
May 3, 2016
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Gaetano T. Montelione, Masayori Inouye, Yuefeng Tang, Monica Roth, William Schneider
Abstract: There is provided a fusion protein suitable for secretion of more than one polypeptide(s) of interest (POI) comprising a signal peptide, a POI, a passenger domain comprising a beta stem domain from an autotransporter protein, and a translocator domain from an autotransporter protein, wherein the beta stem-forming sequence of the passenger domain is essentially intact and the POI(s) is/are fused to the beta stem domain.
Abstract: Disclosed herein are an N-terminal modified PEG-TRAIL conjugate and a preparation method and use thereof. The PEG-TAIL conjugate has pharmaceutical activity identical or similar to that of native TRAIL (TNF-related apoptosis-inducing ligand) with extended in vivo half-life and enhanced stability. Compared to native TRAIL, the PEG-TAIL conjugate exhibits high solubility and solution stability, with highly improved pharmacokinetic profiles. Thus, the PEG-TAIL conjugate may be very useful for preventing and treating proliferative diseases and autoimmune diseases.
Type:
Grant
Filed:
June 12, 2007
Date of Patent:
April 26, 2016
Assignee:
Theraly Pharmaceuticals Inc.
Inventors:
Kang Choon Lee, Su Young Chae, Yu Seok Youn, Won Bae Kim, Sung Kwon Lee
Abstract: The invention relates to trans-acting ligand-responsive nucleic acids and uses thereof. In particular, a ligand responsive nucleic acid comprises an effector domain and an aptamer domain that is responsive to a ligand.
Abstract: The present invention pertains to a method for selecting at least one eukaryotic host cell expressing a product of interest. The method entails providing a plurality of host cells which are dependent upon folate uptake and contain polynucleotides encoding for the product of interest and a DHFR enzyme. The cells are cultured in a selective culture medium containing at least an inhibitor of DHFR and folate. The expressed cells are then selected.
Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
Type:
Grant
Filed:
October 13, 2011
Date of Patent:
April 12, 2016
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
Abstract: There is provided a recombinant bacterium comprising at least one overexpressed acyl-ACP thioesterase gene, and wherein at least one gene from the tricarboxylic acid cycle or glycolysis or both is inactivated. There is also provided a method for producing fatty acids, said method comprising culturing bacteria comprising at least one overexpressed acyl-ACP thioesterase gene in a growth medium in a container having walls; allowing said bacteria to secrete fatty acids; and collecting said fatty acids. Acid supplementation is also shown to increase productivity.
Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
Type:
Grant
Filed:
March 4, 2011
Date of Patent:
April 5, 2016
Assignee:
Merus B.V.
Inventors:
Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout
Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate mTOR activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.
Abstract: The present invention is generally directed to nanometric biomolecular arrays and to a novel approaches for the preparation of such nanoarrays, based on binding of biomolecules, such as avidin, to templates generated by lithographically-anodizing biocompatible ultrathin films on silicon substrates using AFM anodization lithography. The present invention is also directed to methods of using such arrays.
Abstract: A method for identifying test agents that exhibit prebiotic activity on human skin commensal microorganisms and compositions that include such agents. The method includes providing a test culture of a test agent, a human skin commensal microorganism and a minimal carbon medium. The method provides a time efficient and cost effective way to predict in vivo prebiotic activity of a test agent on skin commensal microorganisms.
Type:
Grant
Filed:
November 8, 2012
Date of Patent:
March 22, 2016
Assignee:
The Procter & Gamble Company
Inventors:
Anthony Charles Lanzalaco, Duane Larry Charbonneau, Brian Wilson Howard
Abstract: A light-sensitive G-protein coupled receptor includes a light sensitive extracellular domain and a heterologous intracellular domain capable of modulating an intracellular signaling pathway.
Abstract: The present invention relates to nucleic acid constructs comprising selectable marker genes in a multicistronic transcription unit for use in the generation and selection of eukaryotic host cells for expression of a gene product of interest. For increased stringency of selection, the coding sequence of the selectable marker may be directed preceded by a relatively short functional open reading frame to reduce the efficiency of translation of the selectable marker, and/or the amino acid sequence of the selectable marker may comprise one or more mutations that reduce the level of resistance provide by the mutated marker as compared to its wild type counterpart. The invention further relates to methods for generating eukaryotic host cells for expression of a gene product of interest, wherein these nucleic acid constructs are used, and to methods for producing a gene product of interest wherein thus generated host cells are applied.
Type:
Grant
Filed:
June 15, 2010
Date of Patent:
March 15, 2016
Assignee:
CELLAGENICS B.V.
Inventors:
Arie Pieter Otte, Henricus Johannes Maria Van Blokland, John Antonius Verhees
Abstract: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
Type:
Grant
Filed:
March 24, 2014
Date of Patent:
March 15, 2016
Assignee:
Medimmune Limited
Inventors:
Tristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
Abstract: The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.
Abstract: The present invention provides miniSOG proteins, polynucleotides, and methods of use. When expressed in a bacterial or mammalian cell, miniSOG proteins spontaneously incorporate flavin mononucleotide and produce fluorescence and singlet oxygen upon excitation. Uses include optical and electron microscope imaging, in vivo imaging, detection and localization of protein-protein interactions, and photoablation.
Type:
Grant
Filed:
December 7, 2011
Date of Patent:
March 8, 2016
Assignee:
The Regents of the University of California
Abstract: Vectors expressible in a host that is the rhaBAD promoter region of the L-rhamnose operon operably linked to a transcriptional unit that is: a) a nucleic acid sequence which is heterologous to the host, and b) a prokaryotic signal sequence operably linked to the nucleic acid sequence. The prokaryotic signal sequence is selected from signal peptides of periplasmatic binding proteins for sugars, amino acids, vitamins and ions. The expression of the nucleic acid sequence is controlled by the promoter region. The vector is used for the regulated heterologous expression of a nucleic acid sequence in a prokaryotic host. This is an isolated and purified nucleic acid sequence expressible in a host is the promoter region of the L-rhamnose operon. There is a method for producing a polypeptide in a host using the vector.
Type:
Grant
Filed:
October 14, 2011
Date of Patent:
March 8, 2016
Assignee:
LONZA AG
Inventors:
Johann Brass, Christoph Kiziak, Joachim Klein, Ralf Ostendorp
Abstract: Disclosed herein are methods of predicting whether or not a subject will benefit from treatment with a Src inhibitor on the basis of the expression of one or more of Von Hippel Lindau (VHL), Src, PTP1B, pFAK, HIF-1?, and/or CA-IX in a tumor sample from the subject.
Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
Abstract: Methods are provided to obtain recombinant microbial cells having at least one genetic modification that increase the buoyant density of a recombinant microbial cell or the buoyant density of inclusion bodies produced within a recombinant microbial cell. Exemplified are genetic modifications that increase the buoyant density of a recombinant microbial cell expressing heterologous peptides and polypeptides. Increasing expression of the genes ysaB, glyQ, glyS or a combination thereof within the recombinant microbial cell produces cells or inclusion bodies having higher buoyant density. A similar effect was achieved by decreasing or disrupting expression of the endogenous gltA gene. Increases in buoyant density render peptide production more efficient with respect to time and costs.
Type:
Grant
Filed:
June 21, 2011
Date of Patent:
March 1, 2016
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Ritu Bhalla, Qi Chen, Qiong Cheng, Neeraj Pandey, Pierre E. Rouviere, Kristin Ruebling-Jass, Annapurna Sachan
Abstract: Genes are expressed by culturing cells comprising a host chromosome comprising an integrated artificial chromosome comprising recombinant genes, under conditions whereby each recombinant gene is expressed copy number dependently and position independently. Deletions increase expression from recombinant gene(s) inserted into the artificial chromosome.
Abstract: Compositions and methods are disclosed herein for cloning a donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
March 1, 2016
Assignee:
Synthetic Genomics, Inc.
Inventors:
Gwynedd A. Benders, John I. Glass, Clyde A. Hutchison, III, Carole Lartigue, Sanjay Vashee, Mikkel A. Algire, Hamilton O. Smith, Charles E. Merryman, Vladimir N. Noskov, Ray-Yuan Chuang, Daniel G. Gibson, J. Craig Venter
Abstract: The present invention is directed to HSV-1 vectors which rely on the tetracycline repressor and operator as a means for regulating expression. The vectors utilize VP-16 responsive promoters of HSV to control expression of the tetracycline repressor. The vectors are of particular interest as vehicles for recombinantly expressing genes in vivo.
Abstract: A high-throughput, tiered screening method of indentifying test agents that exhibit prebiotic activity on human skin commensal microorganisms and cosmetic compositions that include such agents. The method includes determining the metabolite level of a culture and comparing the metabolite level to a control value. The assay further comprises performing a plate count using the culture when the metabolite level of the culture is greater than its corresponding control value. The plate count results are compared to another control value, and the test agent is identified as a prebiotic agent when the number of colonies present in the plate count assay of the culture is greater than the second control value.
Type:
Grant
Filed:
November 8, 2012
Date of Patent:
March 1, 2016
Assignee:
The Procter & Gamble Company
Inventors:
Anthony Charles Lanzalaco, Duane Larry Charbonneau, Brian Wilson Howard
Abstract: This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased.
Type:
Grant
Filed:
August 30, 2013
Date of Patent:
March 1, 2016
Assignee:
Generon (Shanghai) Corporation Ltd.
Inventors:
Xiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Bill N. C. Sun, Yuliang Huang
Abstract: The present invention relates to methods for producing transgenic animals using retroviral constructs engineered to carry a transgene(s) of interest.
Type:
Grant
Filed:
September 13, 2002
Date of Patent:
February 23, 2016
Assignee:
CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventors:
David Baltimore, Elizabeth J. Hong, Carlos Lois-Caballe, Shirley Pease
Abstract: The present invention provides a protein, specifically Parietochloris incisa acetohydroxyacid synthase, and methods for producing branched-chain amino acid in a cell. The present invention further provides polypeptides and polynucleotides useful for conferring herbicide resistance in a cell or an organism. In particular, the present invention discloses a mutated acetohydroxyacid synthase which is resistant to herbicides.
Type:
Grant
Filed:
October 4, 2012
Date of Patent:
February 23, 2016
Assignee:
Ben-Gurion University of the Negev Research and Development Authority
Inventors:
Omer Grundman, Inna Khozin-Goldberg, Zvi Hacohen, Michal Shapira, Dina Raveh, Sammy Boussiba, Boris Zorin
Abstract: The present invention is an attenuated mutant strain of Streptococcus pneumonia that has a mutation in the FtsY gene. Vaccines, kits and methods for protecting a subject against Streptococcus pneumonia disease or colonization using the attenuated mutant strain are also provided.
Type:
Grant
Filed:
September 19, 2012
Date of Patent:
February 23, 2016
Assignee:
St. Jude Children's Research Hospital
Inventors:
Jason W. Rosch, Elaine I. Tuomanen, Jonathan A. McCullers
Abstract: Compositions and methods are disclosed herein for cloning a synthetic or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.
Type:
Grant
Filed:
May 19, 2010
Date of Patent:
February 23, 2016
Assignee:
Synthetic Genomics, Inc.
Inventors:
Gwynedd A. Benders, John I. Glass, Clyde A. Hutchison, Carole Lartigue, Sanjay Vashee, Mikkel A. Algire, Hamilton O. Smith, Charles E. Merryman, Vladimir N. Noskov, Ray-Yuan Chuang, Daniel G. Gibson, J. Craig Venter
Abstract: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods and compositions for phage microarray profiling of cancer (e.g., prostate, lung, or breast cancer). The present invention further provides novel markers useful for the diagnosis, characterization, and treatment of cancers.
Type:
Grant
Filed:
October 28, 2010
Date of Patent:
February 23, 2016
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN